★★★★★ 5
Beautiful shoe but too narrow
Size: 10 Wide, Color: Navy Grainy Leather
Too narrow
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on May 24, 2026
soul trial oral semaglutide cardiovascular outcomes nejm 2025 results GLP-1 receptor agonists are increasingly used to treat type 2 diabetes and #obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal. Read
Marsoni
M251S
Get it in 3 business days with 1 day shipping.
Friday, May 29
Mean (SE) 24 Hour Plasma Ghrelin Profiles in 13 Obese Subjects before Download Scientific Diagram Which weight loss medication is right for you? , With so many options now available in Singapore, the choice depends on your biology and your lifestyle., Ozempic (Semaglutide): The gold standard Semaglutide Weight Loss Program Healthogenics Semaglutide Side Effects Guide: Complete Safety Profile and Management Strategies Beverly Hills Rejuvenation Center What Is Semaglutide? Science & Benefits Explained Empire On Demand
Quick Dispatch:
Your soul trial oral semaglutide cardiovascular outcomes nejm 2025 results GLP-1 receptor agonists are increasingly used to treat type 2 diabetes and #obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal. Read orders ship within 1-2 business days.
Delivery Options:
- Standard: 3-7 business days
- Fast: 2-3 business days
- Express: 1-2 business days
Order Tracking:
You'll receive a tracking link by email once your soul trial oral semaglutide cardiovascular outcomes nejm 2025 results GLP-1 receptor agonists are increasingly used to treat type 2 diabetes and #obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal. Read ships.
Need Help?
Questions about soul trial oral semaglutide cardiovascular outcomes nejm 2025 results GLP-1 receptor agonists are increasingly used to treat type 2 diabetes and #obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal. Read, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for soul trial oral semaglutide cardiovascular outcomes nejm 2025 results GLP-1 receptor agonists are increasingly used to treat type 2 diabetes and #obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal. Read in your area.
Get Shipping Estimates
Exchange/Return Notes
- We offer a 30-day return/exchange service after receiving.
- Final sale items are not eligible for returns or exchanges.
- To process your return/exchange, please contact us at [email protected]
- Please click here for more details>>> Return & Exchange Policy
You may also like
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
29.29
💥Soul study group recently shared the result of their study :✔️ Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes @NEJM 🟡 n=9650 🟡 42.4 %had history of CKD 🟡 Majority
23.93
Oral semaglutide found to lower risk of heart failure events in people with type 2 diabetes
26.32
Oral Semaglutide Reduces Cardiovascular Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial
20.73
SOUL (Semaglutide cardiOvascular oUtcomes triaL) in individuals with
22.36
An oral formulation of semaglutide lowered the risk major adverse cardiovascular events by 14% in four years, with no change in safety profile compared to placebo, according to the SOUL study. #ACC25
20.00
Trial Scorecard: SOUL
20.04
4.3 ★★★★★
Based on 1518 reviews
Sort
Product Reviews
★★★★★ 5
Looks good feels good
Size: 13 Wide, Color: Black
I've had them 2 weeks and love them. Took a little breaking in but they feel great now.
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on April 8, 2026
★★★★★ 4
Very narrow
Size: 10 Wide, Color: Cognac
Run narrow. For very narrow feet. Wide width fits like a regular width.
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on February 9, 2026
★★★★★ 5
Comfortable Shoes Right Out of the Box
Size: 9, Color: Black
I bought these shoes for my husband. He has a very hard time finding quality, comfortable shoes. These shoes are just as comfortable as his New Balance. He uses them as a dress shoe and wears them at least once a week. There was no break in period necessary. They were comfortable right out of the box! The only thing we didn't like was the white sole color. Once I knew he was going to keep them, I used a black sharpie marker to color the soles black. Instant amazing, comfortable dress shoes. They were well worth the cost. If you or your SO needs a comfortable pair of shoes, we highly recommend them.
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on September 2, 2025
★★★★★ 1
Paid for new, received used.
Size: 9.5 Wide, Color: Cognac, Size: 9.5 Wide, Color: Cognac
Arrived dirty as if someone whore it for more than a few days. Maybe I was mistaken, but I saw nothing about “previously used” on the Amazon page. Returned it.
I would suggest that the company use quality control when it comes to shipping. The shoes seem find otherwise. I ordered 9.5 and it was just a bit tight. If I reorder I will go for size 10.
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on June 11, 2026
recommand products
GLP-1 is a Good Little Protein
27.77
Multiple target tissue effects of GLP-1 analogues on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)
27.29
SAHPRA warns the public about GLP-1 products sold through social media platforms
20.76
The New York Times spotlighted MEDVi. The FDA had already warned the self-proclaimed 'fastest growing company in history.'
21.18
The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis
24.15